Skip to main content
Clinical Trials/NCT03523910
NCT03523910
Completed
N/A

Right Ventricular Pulmonary Vascular Interaction in Pulmonary Hypertension

University of Wisconsin, Madison0 sites14 target enrollmentApril 25, 2012

Overview

Phase
N/A
Intervention
Not specified
Conditions
Pulmonary Arterial Hypertension (PAH)
Sponsor
University of Wisconsin, Madison
Enrollment
14
Primary Endpoint
The primary outcome is to comprehensively quantify right ventricular and pulmonary vascular function at rest and with exercise using magnetic resonance imaging.
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The goals of this study were two-fold. First, the attempt to quantify the relationships between pulmonary arterial stiffness, right ventricular function and the efficiency of ventricular-vascular interactions in patients with pulmonary arterial hypertension (PAH). Second, the attempt to quantify the effects of exercise on pulmonary arterial stiffness, pulmonary vascular resistance, right ventricular function and the efficiency of ventricular-vascular interactions in patients with PAH.

Detailed Description

The goals of this study are to quantify right ventricular-pulmonary vascular interactions in different types of PAH, to determine the temporal changes in these interactions with PAH progression and to quantify the effects of exercise on right ventricular function. The inclusion of the subpopulation of PAH patients with systemic sclerosis (SSc) was a result of the anticipation that this group has worse arterial stiffening than other groups, and consequently more inefficient right ventricular-pulmonary vascular interactions, which account for their worse prognosis.

Registry
clinicaltrials.gov
Start Date
April 25, 2012
End Date
February 13, 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of pulmonary arterial hypertension or a subtype
  • Referred for right heart catheterization
  • Age between 18 and 80 years
  • New York Heart Association (NYHA) functional class I, II, or III

Exclusion Criteria

  • Recent syncope (within 1 year)
  • Severe skeletal or muscle abnormalities prohibiting exercise
  • Mixed etiology pulmonary arterial hypertension
  • Severe lung disease
  • Test results indicating severe obstruction
  • Total lung capacity \< 60%
  • Pregnancy or breastfeeding
  • NYHA class IV patient
  • Contraindications to magnetic resonance imaging
  • Kidney dysfunction as determined by an estimated glomerular filtration rate (eGFR) of \< 30 mL/min/1.73m2

Outcomes

Primary Outcomes

The primary outcome is to comprehensively quantify right ventricular and pulmonary vascular function at rest and with exercise using magnetic resonance imaging.

Time Frame: Up to 24 months

The hypotheses will be tested by comprehensively quantifying ventricular and vascular function in subjects with idiopathic pulmonary arterial hypertension, systemic sclerosis pulmonary arterial hypertension, and chronic thromboembolic pulmonary hypertension, using investigational magnetic resonance angiography techniques.

Similar Trials